The Centers for Medicare & Medicaid Services finalized a rule on Nov. 5 that sets a permanent framework for how Medicare negotiates prices on high-cost drugs. The agency’s announcement says the rule governs the Medicare Drug Price Negotiation Program beginning with prices that take effect in 2029. CMS Administrator Dr. Mehmet Oz said President Trump “directed us to lower drug costs for Americans using every tool at our disposal.”
The rule does not change what anyone pays at the pharmacy counter this winter, and CMS states no savings figure for it. What it settles is the machinery: which drugs get picked, how a second round of talks works and where the program’s limits sit. People who take a costly brand-name drug under Part D, or get one administered under Part B, are the ones the rule is aimed at, since those are the drugs eligible for selection.
Stay ahead of government payment news: Miss an enrollment or claim deadline and the money can be gone. Join the Retirement Money Brief and we’ll send you our 2026 Government Check Reality Tracker as a welcome gift.
Get the Brief + the check tracker →
We may earn a commission from links on this page.
What does the rule lock in?
The program’s first rounds, for prices taking effect in 2026 through 2028, were carried out through program instruction and guidance. A CMS fact sheet says the final rule, labeled CMS-4215-F, writes the program’s policies into regulation for 2029 and every year after, and that the older guidance is now expiring. The rule takes effect Dec. 5, 2026.
That matters because a rule is harder to change than a guidance document. Drugmakers and plans now have a fixed set of procedures to plan around, rather than instructions that could be revised from one cycle to the next. Oz said the rule “provides additional tools to help CMS negotiate better deals,” with greater savings for taxpayers and beneficiaries as the stated aim.
Which drugs come next, and when?
CMS will pick up to 20 drugs covered under Part D or payable under Part B for the fourth round, and it may also pick drugs for renegotiation. The agency has set Feb. 1, 2027 as the date it publishes that list, along with a list of up to 30 top negotiation-eligible drugs, according to its timeline for the 2029 cycle.
Drugmakers have until Feb. 28, 2027 to sign agreements. CMS sends its first price offers by June 1, 2027, and the final offer is due by Sept. 30. Negotiations end Nov. 1, 2027, the agreed prices must be published by Nov. 30, 2027, and they take effect Jan. 1, 2029. For a person who takes one of the picked drugs, the price change is more than two years away.
How does renegotiation work?
The rule lets CMS reopen a price it has already agreed to. It codifies the eligibility and selection criteria, the information the agency can consider and the way data is submitted, and says renegotiation will follow the same process as initial negotiation wherever practicable. Drugmakers may voluntarily send CMS information to consider when it decides what to renegotiate, with a December 2026 deadline.
Drugs picked for renegotiation already have agreements in place, so those makers do not need to sign a new one. For renegotiation, CMS will treat a drug’s earlier agreed price as one of the manufacturer-specific factors it weighs.
Where do combination drugs and small biotechs fit?
The rule closes what CMS calls a program integrity risk. A manufacturer could add an active ingredient to an existing drug, create a new formulation with a different route of administration and potentially avoid selection or the negotiated price. CMS finalized its proposed fix: a fixed-combination product that shares active ingredients with another product from the same application holder is evaluated together with it, across all dosage forms and strengths.
The agency says this removes the incentive for a maker to shift patients to the new version. A separate provision, required by law, creates a temporary price floor for certain small biotech drugs in 2029 and 2030, barring CMS from offering or accepting a counteroffer below it. After public comment, CMS also changed how one pricing measure, known as non-FAMP, is treated in the ceiling calculation for those drugs.
The rule also spells out how CMS decides whether generics and biosimilars are genuinely being marketed, the timing of those reviews and how it monitors drugs deemed ineligible or deselected. It clarifies how withdrawn approvals for particular uses count under the orphan drug exclusion, following amendments in a 2025 federal law.
What must Part D plans do with a negotiated drug?
Part D plans have to include selected drugs that have a negotiated price in effect on their formularies, the lists of covered drugs, and the price used for payment cannot exceed the negotiated price plus any dispensing fees. The fact sheet notes that plans may remove a selected drug only where the regulation allows it.
CMS says it will release final guidance this fall on how manufacturers deliver negotiated prices in 2028, including for Part B drugs, and plans to put the rules for 2029 and later into rulemaking in 2027. Those pieces are still to come, and they decide how the discounts reach a person’s actual costs at the pharmacy.
Paying for Medicare drugs before the new prices arrive?
The negotiated prices from this rule’s first cycle do not take effect until Jan. 1, 2029, so premiums, drug costs and surcharges in the meantime are still set by today’s rules. Anyone on Medicare who overpays in the gap loses real money each month.
Cut Your Medicare Bill holds ten moves to pay less for the same care, including the $2,100 drug cap for 2026 and what counts toward it, and a single table of 2026 Medicare costs at a glance. It also covers the Form SSA-44 surcharge appeal and monthly drug payments in place of one big bill early in the year.
Get the drug-cap guide and Medicare cost table to cut your bill before 2029 →
This article was produced with AI assistance and edited for accuracy against the sources linked above.
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
